Clinical Trials > Targeted Therapy
Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
A clinical trial of a new drug known as 9-ING-41, that will take place in
patients with tumors or cancers that affect the blood and lymph system.
9-ING-41 be assessed as a standalone drug as well as being assessed
when taken with chemotherapy drugs.
A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma
Patients with intrahepatic cholangiocarcinoma who enroll in this study will receive either Melphalan with the investigational Hepatic Delivery System (called Melphalan/HDS) or Cisplatin and Gemcitabine alone, which is standard of care. Patients who enroll will receive gem/cis followed by melphalan, compared to gem/cis.read more
This is an open-label, nonrandomized, Phase 1 dose-escalation, dose-expansion, and Phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.read more
ZWI-ZW25-101 is a clinical study of ZW25 as a treatment for advanced (unresectable) and/or metastatic HER2-expressing cancers, including cholangiocarcinoma. Patients will receive once a week or once every other two weeks by IV infusion and will be monitored for safety and to determine response to the drug.read more
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) AlterationsStudy Name Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations ClinicalTrials.gov Identifier (if applicable) NCT01948297 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted Therapy Study Center Institution Name The University of Texas MD Anderson Cancer Center Institution Address 1515 Holcombe Blvd City Houston State Texas Zip Code 77030 Phone (713) 745-0746 Website http://www.mdanderson.org List additional Institutions (include address, phone number, and website) Dana-Farber Cancer Institute – Boston, Massachusetts, United States Massachusetts General Hospital – Boston, Massachusetts, United States Memorial Sloan-Kettering Hospital – New York, New York, United States Seoul National University Hospital – Seoul, Republic of Korea National Cancer Center Singapore – Singapore, Singapore Vall d’Hebron University Hospital – Barcelona, Spain Taipei... read more
A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors With FGF/FGFR-Related Abnormalities
FGFR gene abnormalities have been linked to various cancers. TAS-120 is an inhibitor of FGFR and therefore is being studied as a therapy for cancer. TAS-120 is a pill that you will take every day. You will see a doctor every 21 days, but you may have blood tests performed more often. You will have your cancer re-staged every 6-9 weeks.read more
A clinical trial to study AG-120 in previously treated patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.read more
A Clinical trial to study the efficacy and safety of INCB054828 in patients with Advanced/Metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocations, other FGF/FGFR alterations or negative FGF/FGFR alterations who failed previous therapy.read more
DeLiver-FGFR: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
FGFR2 genetic alterations (changes) are associated with different types of cancer. A drug that inhibits the activity of FGFR2 may be beneficial for the treatment of these cancers. In a recent trial, patients with intrahepatic cholangiocarcinoma with a genetic alteration known as “FGFR2 gene fusion”, benefited the most from treatment with ARQ 087.read more
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy
This Phase II clinical trial will establish the effectiveness of BGJ398 in patients harboring the FGFR2 gene fusion/translocation, which are errors in the DNA. Adult patients with histologically or cytologically confirmed (tumor biopsy), advanced or metastatic cholangiocarcinoma harboring the FGFR2 gene fusion/ translocation are eligible for enrollment. Phase II clinical trials give doctors more information about the safety of the drug and how well it works.
Approximately 55 adult patients over age 18, both male and female will be enrolled. All patients will receive oral BGJ398, once daily, on a three weeks on (21 days), one week off (7 days) scheduleread more